Ceftriaxone v penicillin and gentamicin — Competitive Intelligence Brief

Ceftriaxone v penicillin and gentamicin (Ceftriaxone v penicillin and gentamicin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Third-generation cephalosporin. Area: Metabolic.

marketed Third-generation cephalosporin Penicillin-binding proteins (PBPs) Metabolic Small molecule

Target snapshot

Ceftriaxone v penicillin and gentamicin (Ceftriaxone v penicillin and gentamicin) — Kamuzu University of Health Sciences. Ceftriaxone inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs).

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Ceftriaxone v penicillin and gentamicin TARGET	Ceftriaxone v penicillin and gentamicin	Kamuzu University of Health Sciences	marketed	Third-generation cephalosporin	Penicillin-binding proteins (PBPs)
Fortaz	Ceftazidime	Pai Holdings Pharm	marketed	Third-generation cephalosporin	Bacterial cell wall	1985-01-01
Comparison 1: Prehospital Ceftriaxone	Comparison 1: Prehospital Ceftriaxone	Dr. Damon Scales	marketed	Third-generation cephalosporin	Penicillin-binding proteins (PBPs)
Cefotaxime/ceftriaxone	Cefotaxime/ceftriaxone	Centre Hospitalier Universitaire de Besancon	marketed	Third-generation cephalosporin	Penicillin-binding proteins (PBPs)
Omnicef Cap.	Omnicef Cap.	Korea United Pharm. Inc.	marketed	Third-generation cephalosporin	Penicillin-binding proteins (PBPs)
Ceftazidime Injection	Ceftazidime Injection	Murdoch Childrens Research Institute	marketed	Third-generation cephalosporin	Penicillin-binding proteins (PBPs)
Ceftriaxone for Injection	Ceftriaxone for Injection	The University of Queensland	marketed	Third-generation cephalosporin	Penicillin-binding proteins (PBPs)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Third-generation cephalosporin class)

1. Abbott · 1 drug in this class
2. Centre Hospitalier Universitaire de Besancon · 1 drug in this class
3. Dr. Damon Scales · 1 drug in this class
4. Fundación Pública Andaluza para la gestión de la Investigación en Sevilla · 1 drug in this class
5. Kamuzu University of Health Sciences · 1 drug in this class
6. Korea United Pharm. Inc. · 1 drug in this class
7. Merck Sharp & Dohme LLC · 1 drug in this class
8. Murdoch Childrens Research Institute · 1 drug in this class
9. Pai Holdings Pharm · 1 drug in this class
10. RESnTEC, Institute of Research · 1 drug in this class